XML 38 R23.htm IDEA: XBRL DOCUMENT
v3.8.0.1

STOCK-BASED COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
STOCK-BASED COMPENSATION |
14. | STOCK-BASED COMPENSATION:
Equity Compensation Plan In 1995, the Board of Directors of the Company adopted a stock option plan, which was most recently amended and restated in 2014 and is now called the Equity Compensation Plan. The Equity Compensation Plan provides for the granting of incentive and nonqualified stock options, shares of common stock, stock appreciation rights and performance units to employees, directors and consultants of the Company. Stock options are exercisable over periods determined by the Compensation Committee, but for no longer than 10 years from the grant date. Through December 31, 2017, the Company’s shareholders have approved increases in the number of shares reserved for issuance under the Equity Compensation Plan to 10,500,000, and have extended the term of the plan through 2024. As of December 31, 2017, there were 2,497,948 shares that remained available to be granted under the Equity Compensation Plan. Stock Options The following table summarizes the stock option activity during the year ended December 31, 2017 for all the grants under the Equity Compensation Plan (in thousands, except share and per share data):
|  | Options |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2017 |  |  | 3,500 |  |  | $ | 15.99 |
Granted |  |  | — |  |  |  | — |
Exercised |  |  | (2,250 | ) |  |  | 16.89 |
Forfeited/ Expired |  |  | (750 | ) |  |  | 17.24 |
Cancelled |  |  | — |  |  |  | — |
Outstanding at December 31, 2017 |  |  | 500 |  |  |  | 10.04 |
Vested and expected to vest |  |  | 500 |  |  |  | 10.04 |
Exercisable at December 31, 2017 |  |  | 500 |  |  | $ | 10.04 |
No stock options were granted during the years ended December 31, 2017, 2016 or 2015. A summary of stock options outstanding and exercisable by price range at December 31, 2017 is as follows (in thousands, except share and per share data):
|  | Outstanding and Exercisable |
Exercise Price |  | Number of Options Outstanding at December 31, 2017 |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value (A) |
$10.04-$15.06 |  |  | 500 |  |  |  | 1.5 |  |  | $ | 10.04 |  |  | $ | 81 |
(A) | The difference between the stock option’s exercise price and the closing price of common stock at December 31, 2017.
The total intrinsic value of stock options exercised during the years ended December 31, 2017, 2016 and 2015 was $146,000, $507,000 and $12.0 million, respectively. There was no compensation expense recognized for the years ended December 31, 2017, 2016, and 2015. During the year ended December 31, 2015, 13,959 shares of common stock, with a fair value of $429,000, were tendered to net share settle the exercise of options. During the years ended December 31, 2017 and 2016, no shares of common stock were tendered to net share settle the exercise of options. In connection with the exercise of options during the year ended December 31, 2015, 30,186 shares with a fair value of $1.3 million were withheld in satisfaction of employee tax withholding obligations. Stock Awards The following table summarizes the activity related to restricted stock unit (“RSU”) share based payment awards:
|  | Number of Shares |  |  | Weighted- Average Grant-Date Fair Value |
Unvested, January 1, 2017 |  |  | 131,119 |  |  | $ | 45.44 |
Granted |  |  | 69,497 |  |  |  | 116.58 |
Vested |  |  | (84,407 | ) |  |  | 46.38 |
Forfeited |  |  | (5,526 | ) |  |  | 54.99 |
Unvested, December 31, 2017 |  |  | 110,683 |  |  | $ | 88.91 |
The weighted average grant-date fair value of RSU awards granted was $116.58, $53.85 and $41.09 during the years ended December 31, 2017, 2016 and 2015, respectively. The fair value as of the respective vesting dates of RSUs was $8.3 million, $5.4 million and $5.6 million for 2017, 2016 and 2015, respectively. The following table summarizes the activity related to restricted stock award (“RSA”) share based payment awards:
|  | Number of Shares |  |  | Weighted- Average Grant-Date Fair Value |
Unvested, January 1, 2017 |  |  | 749,955 |  |  | $ | 46.64 |
Granted |  |  | 3,604 |  |  |  | 83.25 |
Vested |  |  | (173,022 | ) |  |  | 47.14 |
Forfeited/ Canceled |  |  | (600 | ) |  |  | 49.70 |
Unvested, December 31, 2017 |  |  | 579,937 |  |  | $ | 46.72 |
The weighted average grant-date fair value of RSA awards granted was $83.25, $65.37 and $43.49 during the years ended December 31, 2017, 2016 and 2015, respectively. The fair value as of the respective vesting dates of RSAs was $14.8 million, $8.6 million and $7.3 million for 2017, 2016 and 2015, respectively. Restricted Stock Awards and Units The Company has issued restricted stock awards and units to employees and non-employee members of the Scientific Advisory Board with vesting terms of one to six years. The fair value is equal to the market price of the Company’s common stock on the date of grant for awards granted to employees and equal to the market price at the end of the reporting period for unvested non-employee awards or upon the date of vesting for vested non-employee awards. Expense for restricted stock awards and units is amortized ratably over the vesting period for the awards issued to employees and using a graded vesting method for the awards issued to non-employee members of the Scientific Advisory Board. For the years ended December 31, 2017, 2016 and 2015, the Company recorded, as compensation charges related to restricted stock awards and units issued to employees and non-employees, selling, general and administrative expense of $8.5 million, $6.6 million and $5.8 million, manufacturing expense of $443,000, $1.1 million and $178,000 and research and development expense of $1.6 million, $1.7 million and $1.9 million, respectively. The majority of the Company’s restricted stock awards and units that vested in 2017, 2016 and 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate tax authorities. The total shares withheld were approximately 89,661, 84,135 and 99,345 for 2017, 2016 and 2015, respectively, and were based on the value of the restricted vesting dates as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to taxing authorities were $7.8 million, $4.5 million and $4.2 million in 2017, 2016 and 2015, respectively, and are reflected as a financing activity within the consolidated statements of cash flows. For the years ended December 31, 2017, 2016 and 2015, the Company recorded as compensation charges related to all restricted stock units to non-employee members of the Scientific Advisory Board whose unvested shares are marked to market each reporting period, research and development expense of $976,000, $242,000 and $426,000, respectively. Board of Directors Compensation The Company has granted restricted stock units to non-employee members of the Board of Directors with vesting terms of approximately one year. The fair value is equal to the market price of the Company’s common stock on the date of grant. The restricted stock units are issued and expense is recognized ratably over the vesting period. For the years ended December 31, 2017, 2016 and 2015, the Company recorded compensation charges for services performed related to all restricted stock units granted to non-employee members of the Board of Directors, selling and administrative expense of $1.6 million, $1.5 million and $865,000, respectively. Restricted stock issued to non-employee members of the Board of Directors during 2017, 2016 and 2015 was 27,500, 30,000 and 29,167 shares, respectively. As of December 31, 2017, the total unrecognized cost related to RSUs and RSAs was $30.2 million, which the Company expects to recognize over a weighted average period of 2.47 years. Performance Unit Awards The following table summarizes the activity related to performance unit awards (“PSU”) share based payment awards:
|  | Number of Shares |  |  | Weighted- Average Grant-Date Fair Value |
Unvested, January 1, 2017 |  |  | 93,769 |  |  | $ | 46.02 |
Granted |  |  | 24,664 |  |  |  | 105.65 |
Vested |  |  | (45,118 | ) |  |  | 39.72 |
Forfeited |  |  | — |  |  |  | — |
Unvested, December 31, 2017 |  |  | 73,315 |  |  | $ | 62.36 |
During the years ended December 31, 2017 and 2016, respectively, the Company granted 24,664 and 25,045 performance units, of which 7,817 and 12,520 are subject to performance-based vesting requirements and 7,821 and 12,525 are subject to market-based vesting requirements, and will vest over the terms described below. In 2017, there were also 9,026 incremental performance-based shares that vested resulting from an increased vesting factor based on Company performance. The weighted average grant date fair value of the performance unit awards granted was $105.65, $58.46 and $35.98 during the years ended December 31, 2017, 2016 and 2015, respectively, as determined by the Company’s common stock on date of grant for the units with performance-based vesting and a Monte-Carlo simulation for the units with market-based vesting. Each performance unit award is subject to both a performance-vesting requirement (either performance-based or market-based) and a service-vesting requirement. The performance-based vesting requirement is tied to the Company's cumulative revenue growth compared to the cumulative revenue growth of companies comprising the Nasdaq Electronics Components Index, as measured over a specific performance period. The market-based vesting requirement is tied to the Company's total shareholder return relative to the total shareholder return of companies comprising the Nasdaq Electronics Components Index, as measured over a specific performance period. The maximum number of performance units that may vest based on performance is two times the shares granted. Further, if the Company's total shareholder return is negative, the performance units may not vest at all. For the years ended December 31, 2017, 2016 and 2015, the Company recorded, as compensation charges related to all performance stock units, selling, general and administrative expense of $1.2 million, $1.3 million and $854,000, manufacturing expense of $119,000, $133,000 and $17,000 and research and development expenses of $276,000, $356,000 and $237,000, respectively. In connection with the vesting of performance units during the year ended December 31, 2017, 19,217 shares with an aggregate fair value of $1.6 million were withheld in satisfaction of employee tax withholding obligations. During the year ended December 31, 2016, no shares were withheld in satisfaction of employee tax withholding obligations. As of December 31, 2017, the total unrecognized compensation cost related to PSUs was $1.9 million, which the Company expects to recognize over a weighted average period of 1.69 years. Employee Stock Purchase Plan On April 7, 2009, the Board of Directors of the Company adopted an Employee Stock Purchase Plan (ESPP). The ESPP was approved by the Company’s shareholders and became effective on June 25, 2009. The Company has reserved 1,000,000 shares of common stock for issuance under the ESPP. Unless terminated sooner by the Board of Directors, the ESPP will expire when all reserved shares have been issued. Eligible employees may elect to contribute to the ESPP through payroll deductions during consecutive three-month purchase periods, the first of which began on July 1, 2009. Each employee who elects to participate will be deemed to have been granted an option to purchase shares of the Company’s common stock on the first day of the purchase period. Unless the employee opts out during the purchase period, the option will automatically be exercised on the last day of the period, which is the purchase date, based on the employee’s accumulated contributions to the ESPP. The purchase price will equal 85% of the lesser of the closing price per share of common stock on the first day of the period or the last business day of the period. Employees may allocate up to 10% of their base compensation to purchase shares of common stock under the ESPP; however, each employee may purchase no more than 12,500 shares on a given purchase date, and no employee may purchase more than $25,000 of common stock under the ESPP during a given calendar year. For the years ended December 31, 2017, 2016 and 2015, the Company issued 9,730, 9,386 and 12,246 shares, respectively, of its common stock under the ESPP, resulting in proceeds of $734,000, $439,000 and $354,000, respectively. For the years ended December 31, 2017, 2016 and 2015, the Company recorded charges of $69,000, $45,000 and $34,000, respectively, to selling, general and administrative expense, $46,000, $15,000, $9,000, respectively, to manufacturing expense and $94,000, $67,000 and $50,000, respectively, to research and development expense, related to ESPP equal to the amount of the discount and the value of the look-back feature.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration